SHAREVAC
LIVE

Serial Number

98697887

Owner

CUREVAC SE

Attorney

Jennifer Fraser

Filing Date

Aug 14, 2024

Add to watchlist:

No watchlists yet
View on USPTO

SHAREVAC Trademark

Serial Number: 98697887 • Registration: 7972673

SHAREVAC is a trademark filed by CUREVAC SE on August 14, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 7 (Machinery), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

CUREVAC SE (14 trademarks)

FRIEDRICH-MIESCHER-STR. 15
TÜBINGEN 72076 , DE

Entity Type: 94

Trademark Details

Filing Date

August 14, 2024

Registration Date

October 7, 2025

Published for Opposition

August 19, 2025

Goods & Services

Scientific and laboratory apparatus for chemical synthesis; laboratory equipment, namely, mobile laboratory equipped with scientific or laboratory apparatus for chemical synthesis; laboratory equipment, namely, mobile laboratory equipped with scientific or laboratory apparatus for purification and analysis of synthesized compounds; laboratory equipment, namely, mobile device for the synthesis of macromolecules; Scientific and laboratory apparatus for chemical or biological analysis and/or synthesis; laboratory equipment, namely, mobile production station of biological macromolecules for laboratory or and for cell culturing for therapeutic use; Bioreactors for laboratory or and for cell culturing for therapeutic use

Bioreactors for use in manufacturing biopharmaceuticals; Filling machines, in particular for use for filling biopharmaceutical compositions into containers; Industry roboters being industrial robots

Chemical preparations for medical use, in particular biological macromolecules, for therapeutic and preventive treatment of tumor diseases, infectious diseases, autoimmune disorders and allergies, for treatment of inherited genetic diseases or for protein or enzyme replacement therapy, and for treatment of neurological, neuromuscular, neurodegenerative and cardiovascular diseases, and for treatment of metabolic disorders; Pharmaceutical preparations namely, immunostimulants, in particular for human or veterinary medical purposes; pharmaceutical preparations, namely, vaccines, in particular for human or veterinary medical purposes; pharmaceutical preparations, namely, adjuvant immunostimulants; pharmaceuticals and medicaments containing biological macromolecules, in particular for human or veterinary purposes for the treatment of neurological, neuromuscular, neurodegenerative and cardiovascular diseases, for the treatment of infectious diseases, autoimmune diseases and tumours, for treatment of cancers, for treatment of metabolic diseases and for treatment of heritable genetic diseases and for protein or enzyme replacement therapy; Pharmaceuticals preparations and medicines based on biological macromolecules for the treatment of neurological, neuromuscular, neurodegenerative and cardiovascular diseases, for the treatment or prevention of infectious diseases, allergies, autoimmune disorders and tumour diseases, for the treatment of metabolic disorders and for the treatment of inherited genetic diseases or for protein or enzyme replacement therapy; Gene therapeutic preparations being Nucleic acid macromolecules for in vivo or in vitro expression for human and veterinary use; Dietetic substances adapted for medical use, in particular substances for food supplements; Vaccines

Chemicals and biomolecules, in particular biological macromolecules, for industrial or scientific purposes; Reagents for research purposes

Medical and veterinary services, in particular for therapeutic and preventive treatment of tumour diseases, infectious diseases, autoimmune disorders and allergies, for the treatment of inherited genetic diseases or for protein or enzyme replacement therapy, and for the treatment of neurological, neuromuscular, neurodegenerative and cardiovascular diseases, and for the treatment of metabolic disorders; Vaccination services in the nature of administering vaccines to patients

Scientific and technological services, namely, and scientific research , in particular for identification, testing and characterisation of biological molecules; scientific research in the nature of pre-clinical and clinical testing of macromolecules for others; Custom synthesis of chemical compounds, in particular biological macromolecules

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Oct 7, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Oct 7, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 19, 2025 NPUB
PUBLISHED FOR OPPOSITION
Aug 19, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 13, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 14, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 3, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 3, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 3, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 4, 2025 GNRN
NON-FINAL ACTION E-MAILED
Mar 4, 2025 GNRT
NON-FINAL ACTION WRITTEN
Mar 4, 2025 CNRT
ASSIGNED TO EXAMINER
Feb 20, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 17, 2025 NWOS
NEW APPLICATION ENTERED
Aug 14, 2024 NWAP